Vadodara, January 22nd, 2020
Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 31st December 2019.
Financial Highlights
Revenue for the quarter up 19% to Rs 1209 crores from Rs. 1018 crores
Net Profit for the quarter up 38% to Rs 234 crores from Rs 170 crores
Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “It was a good quarter for the company led by strong growth in the International Markets. We launched 7 products in the US market during the quarter.”
Operational Highlights
International Business
International formulations grew 48% to Rs 664 crores in the quarter.
US Generics grew 61% to Rs 515 crores in the quarter.
Ex-US Sales grew 15% to Rs 149 crores in the quarter.
8 ANDA approvals received during the quarter and total tally stand at 110.
6 ANDA filings during the quarter; Cumulative ANDA filings at 176
India Formulations Business
The India formulations business was Rs 368 crores for the quarter as against Rs 365 crores last year.
API Business
The API business grew 2% to Rs 553 crores as against Rs 540 crores .
2 DMF were filled in the quarter.
